Telix Pharmaceuticals Limited
TLX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TLX
Telix Pharmaceuticals Limited (TLX) is a biopharmaceutical company focused on the development and commercialization of diagnostic imaging agents and therapies for cancer and other diseases, with commercial products Illuccix and Gozellix and a pipeline of product candidates in clinical trials.
Key risk: Sustained profitability uncertain
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.82B
Cash Runway
34.4 moLead Asset
illuccix (Approved)
Next Catalyst
Phase3_Topline · Apr 1, 2027Financial data as of Dec 31, 2025.
Tracking 1 pipeline candidate · 13 clinical trials · 5 catalysts · 1 FDA decision for Telix Pharmaceuticals Limited.
Telix Pharmaceuticals Limited (TLX) is a biopharmaceutical company focused on the development and commercialization of diagnostic imaging agents and therapies for cancer and other diseases, with commercial products Illuccix and Gozellix and a pipeline of product candidates in clinical trials.
- As of December 31, 2025, Telix had $141.9 million in cash and cash equivalents [sec · filed 2026-02-20].
- Total revenue for the year ended December 31, 2025 was $803.8 million, with a net loss of $7.1 million [sec].
- Illuccix was launched in April 2022 and Gozellix in June 2025; both are commercially available in the U.S. and other jurisdictions [sec · filed 2026-02-20].
- Telix continues to conduct clinical trials for product candidates including TLX250-Px and TLX101-Px [sec · filed 2026-02-20].
- The company has a history of significant net losses and may need additional financing to achieve business objectives [sec · filed 2026-02-20].
What works
- Telix has two commercial products, Illuccix and Gozellix, generating revenue in multiple jurisdictions [sec · filed 2026-02-20].
- The company has recognized profits in recent periods, indicating potential for sustained profitability [sec · filed 2026-02-20].
- Telix has a pipeline of product candidates in clinical development, including TLX250-Px and TLX101-Px, targeting additional indications [sec · filed 2026-02-20].
What to weigh
- Telix has a history of significant net losses and cannot guarantee sustained profitability from current product sales [sec · filed 2026-02-20].
- The company may need to raise additional capital to fund operations and clinical development [sec · filed 2026-02-20].
- Clinical development is lengthy and expensive, with uncertain timelines and outcomes; failure of trials could harm the business [sec · filed 2026-02-20].
- Telix relies on third parties for clinical trials and manufacturing, which may not perform satisfactorily [sec · filed 2026-02-20].
From the filings
Quoted directly from source documents.
Cash position as of December 31, 2025
“As of December 31, 2025 , we had $141.9 million in cash and cash equivalents”
SEC filings · February 20, 2026
Illuccix and Gozellix commercial launches
“Although we launched Illuccix in April 2022 and Gozellix in June 2025 and have recognized profits in recent periods”
SEC filings · February 20, 2026
Uncertainty of sustained profitability
“we cannot be certain that our revenue from product sales of Illuccix and Gozellix will be sufficient for us to remain profitable on an annual basis”
SEC filings · February 20, 2026
Need for additional financing
“we may need to continue to rely on additional financing to achieve our business objectives”
SEC filings · February 20, 2026
Catalyst timeline
- 2027-04-01 · Phase3_Topline — Phase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific — Topline data from a Phase 3 study of a prostate-specific agent will be read out, potentially impacting regulatory submissions.
- 2027-11-01 · Phase3_Topline · iodofalan — Phase 3 Topline: A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solutio — Topline results from a pivotal Phase 3 study of Iodofalan (131I) will be reported, which could support marketing authorization.
- 2029-02-28 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Gire — Topline data from a randomized Phase 3 study of 177Lu-TLX250 will be released, informing the therapy's efficacy.
- 2030-12-01 · Phase3_Topline · lutetium — Phase 3 Topline: A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lute — Topline results from a multinational Phase 3 study of a lutetium-based agent will be disclosed.
- 2035-07-28 · Patent_Expiry · ILLUCCIX — Patent/Exclusivity Expiry: ILLUCCIX — Patent or exclusivity for ILLUCCIX expires, potentially allowing generic competition.
Risks & what to watch (4)›
Key risks
- Sustained profitability uncertain — Revenue from Illuccix and Gozellix may not be sufficient to remain profitable annually [sec · filed 2026-02-20].
- Capital needs for operations — Telix may need additional financing to fund R&D and commercialization [sec · filed 2026-02-20].
- Clinical trial risks — Clinical development is lengthy, expensive, and outcomes are uncertain [sec · filed 2026-02-20].
- Dependence on third parties — Reliance on CROs and partners for trials and manufacturing may lead to delays or failures [sec · filed 2026-02-20].
What to watch
- Topline results from Phase 3 study of prostate-specific agent expected April 2027 [catalyst].
- Topline results from Phase 3 study of Iodofalan (131I) expected November 2027 [catalyst].
- Topline results from Phase 3 study of 177Lu-TLX250 expected February 2029 [catalyst].
- Patent/exclusivity expiry for ILLUCCIX in March 2035 [catalyst].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Telix Pharmaceuticals Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Telix Pharmaceuticals Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
34.4 months
D/E 1.80
Lead: Approved
1 candidate
5 upcoming, next in ~214d
2 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$14.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 564,757 | $5.4M |
| lazard asset management llc | 289,917 | $2.8M |
| portland investment counsel inc. | 266,200 | $2.5M |
| morgan stanley | 116,440 | $1.1M |
| schonfeld strategic advisors llc | 34,873 | $334K |
| vanguard personalized indexing management, llc | 33,253 | $318K |
| ubs group ag | 32,300 | $309K |
| xtx topco ltd | 26,007 | $249K |
| iht wealth management, llc | 25,035 | $240K |
| vident advisory, llc | 16,653 | $159K |
Showing top 10 of 32 institutional holders of Telix Pharmaceuticals Limited. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 0.1%
- Days to cover
- 1.5
- Shares short
- 390,717
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Telix Pharmaceuticals Limited?
Telix Pharmaceuticals Limited (TLX) is a biopharmaceutical company focused on the development and commercialization of diagnostic imaging agents and therapies for cancer and other diseases, with commercial products Illuccix and Gozellix and a pipeline of product candidates in clinical trials.
What is Telix Pharmaceuticals Limited's lead drug candidate?
Telix Pharmaceuticals Limited's most advanced tracked candidate is illuccix (Approved).
What is Telix Pharmaceuticals Limited's next catalyst?
Telix Pharmaceuticals Limited's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific " — expected April 1, 2027.
Who is the CEO of Telix Pharmaceuticals Limited?
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D is the chief executive officer of Telix Pharmaceuticals Limited (TLX).
Where is Telix Pharmaceuticals Limited headquartered?
Telix Pharmaceuticals Limited (TLX) is headquartered in North Melbourne, VIC, Australia.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.